azn201312196k1.htm
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of December 2013

 
Commission File Number: 001-11960

 
AstraZeneca PLC
 
 
2 Kingdom Street, London W2 6BD
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X      Form 40-F __

 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______           
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
 
Yes __     No X
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 


 


Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
 
On 19 December 2013, Marc Dunoyer, a Director of the Company notified us that, on 19 December 2013, he purchased 500 AstraZeneca PLC Ordinary Shares of $0.25 each at a price of 3601 pence per share.

Under the Company's Articles of Association, by way of qualification, a Director is required to be the beneficial owner of 500 Ordinary Shares of the Company, such shares to be obtained within two months of the date of his appointment. Mr Dunoyer was appointed a Director on 1 November 2013.

Following this purchase, Mr Dunoyer has a total interest, including an interest under certain of the Company's share plans, in 165,034 AstraZeneca shares.

A C N Kemp
Company Secretary
19 December 2013
 
 

 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 19 December 2013
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary